

FOI 2216

11th March 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Question 1:

How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Response:

Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	Abemaciclib and tamoxifen – 5
Abemaciclib + Fulvestrant	1
Alpelisib + Fulvestrant	0
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	0
Atezolizumab +Nab-paclitaxel/Paclitaxel	0
Capecitabine as a single agent	8
Eribulin as a single agent or in combination	1
Everolimus + Exemestane	0
Fulvestrant as a single agent	Information not held
Lapatinib	0
Neratinib	0
Parp Inhibitors (Olaparib/Talazoparib)	2
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	27

Palbociclib + Fulvestrant	5
Pembrolizumab	0
Platinum (e.g. carboplatin or cisplatin) as a single agent	0
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	7
Ribociclib + Fulvestrant	3
Sacituzumab Govitecan	4
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	Docetaxel - 4 Paclitaxel - 9
Taxane and/or Anthracycline in combination	Pac/carbo - 2 Phesgo Docetaxel and carbo - 1 Docetaxel and phesgo - 3 Paclitaxel and phego - 1 Paclitaxel and Herceptin - 3
Trastuzumab as a single agent or in combination	16
Trastuzumab emtansine	4
Transtuzumab deruxtecan	3
Any other active systemic anti-cancer therapy	Phesgo – 15 Oral vinorelbine – 4 Oral vin and sc Herceptin - 1

Question 2:

Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Response: No

Email: FOI.team@southerntrust.hscni.net